Our findings may shape a novel strategy for platelet-targeted PF4–TGFβ duet intervention of CD4+ T cell immunity and inflammation in the clinical settings of CD4+ T cell disorders, such as atherosclerosis. This evidence concerns the gene TGFB1 and atherosclerosis.